<code id='D3E9F9F88C'></code><style id='D3E9F9F88C'></style>
    • <acronym id='D3E9F9F88C'></acronym>
      <center id='D3E9F9F88C'><center id='D3E9F9F88C'><tfoot id='D3E9F9F88C'></tfoot></center><abbr id='D3E9F9F88C'><dir id='D3E9F9F88C'><tfoot id='D3E9F9F88C'></tfoot><noframes id='D3E9F9F88C'>

    • <optgroup id='D3E9F9F88C'><strike id='D3E9F9F88C'><sup id='D3E9F9F88C'></sup></strike><code id='D3E9F9F88C'></code></optgroup>
        1. <b id='D3E9F9F88C'><label id='D3E9F9F88C'><select id='D3E9F9F88C'><dt id='D3E9F9F88C'><span id='D3E9F9F88C'></span></dt></select></label></b><u id='D3E9F9F88C'></u>
          <i id='D3E9F9F88C'><strike id='D3E9F9F88C'><tt id='D3E9F9F88C'><pre id='D3E9F9F88C'></pre></tt></strike></i>

          focus

          focus

          author:focus    Page View:33
          Rep. Larry Bucshon (R-Ind.) received a significant amount of campaign donations from the pharmaceutical industry in the second quarter of 2023. House Television via AP

          WASHINGTON — The pharmaceutical industry has been flooding the campaign coffers of Rep. Larry Bucshon, a cardiothoracic surgeon and Republican from Indiana, according to a STAT analysis of this quarter’s filings.

          CEOs of pharmaceutical giants, executives of the brand-drug lobby PhRMA, and companies’ political action committees all gave in higher-than-usual numbers to the rank-and-file House member last quarter. The total was nearly $56,000 between April 14 and June 30.

          advertisement

          Bucshon is a member of the House Energy & Commerce Committee, which works on drug pricing issues, and the GOP Doctors Caucus, but he doesn’t hold leadership positions in either.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          knowledge

          Affirmative action in medical school literally saved lives
          Affirmative action in medical school literally saved lives

          AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

          read more
          Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO
          Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

          MollyFerguson/STATThisweek,apreviewoftheTUDCAstudyinALSandthoughtsonhowitmightimpactAmylyxPharmaceut

          read more
          How to save PrEP access — and even expand it
          How to save PrEP access — and even expand it

          UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

          read more

          Eli Lilly reports tirzepatide MASH success during Q4 earnings

          DarronCummings/APTheblockbusterweightlossanddiabetesdrugsoldbyEliLillyalsoappearstoimprovefattyliver